News

Primary central nervous system lymphoma (PCNSL) is an aggressive diffuse large B-cell lymphoma confined to the brain, spinal cord, leptomeninges and eyes. Its pathogenesis is complex, involving ...
Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma ...
A large-scale national study of primary central nervous system lymphoma (PCNSL) in England has revealed stark differences in ...
Subcutaneous epcoritamab as a monotherapy has been used as a method of treatment for R/R follicular lymphoma in patients with 2 or more prior lines of therapy based on previous study results. A ...
Session ID: 2025-07-13:78f3fda439551c1891b6eb9f Player Element ID: vjs_video_3 ...
AbbVie and Genmab are conducting a Phase 3 clinical trial titled A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and ...
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) ...
AbbVie: Epcoritamab Combo Shows High Response Rates In R/R Follicular Lymphoma Trial December 07, 2024 — 08:40 pm EST Written by RTTNews.com for RTTNews -> ...
Epcoritamab, co-developed by AbbVie and Genmab, is an investigational T-cell engaging bispecific antibody administered subcutaneously for R/R FL, a complex blood cancer with limited treatment options.